Table 2.
Adherence and persistence with once-daily teriparatide during the 12-month study period.
| Variable | All (N = 123) | Time frame of treatmenta | |
|---|---|---|---|
| Early (N = 50) |
Later (N = 73) |
||
| Adherence | |||
| MPRb, mean (SD) | 0.702 (0.366) | 0.640 (0.398) | 0.745 (0.339) |
| MPR > 0.8, n (%) | 75 (61.0) | 27 (54.0) | 48 (65.8) |
| Persistence | |||
| Estimated TTDc, days | |||
| 25th percentile | 95 | 60 | 161 |
| 50th percentile | Censored (≥365) | Censored (≥365) | Censored (≥365) |
| 75th percentile | Censored (≥365) | Censored (≥365) | Censored (≥365) |
| Actual TTD, n (%) | |||
| >0 days | 123 (100.0) | 50 (100.0) | 73 (100.0) |
| >60 days | 99 (80.5) | 37 (74.0) | 62 (84.9) |
| >120 days | 91 (74.0) | 33 (66.0) | 58 (79.5) |
| >180 days | 81 (65.9) | 29 (58.0) | 52 (71.2) |
| >240 days | 80 (65.0) | 29 (58.0) | 51 (69.9) |
| >300 days | 76 (61.8) | 28 (56.0) | 48 (65.8) |
| >360 days | 75 (61.0) | 28 (56.0) | 47 (64.4) |
| ≥365 days (censored) | 75 (61.0) | 28 (56.0) | 47 (64.4) |
MPR: medication possession ratio; SD: standard deviation; TTD: time to discontinuation.
aEarly initiators started treatment during months 1–4 of once-daily teriparatide availability, whereas later initiators started treatment during months 5–8 of once-daily teriparatide availability.
bThe sum of the days' supply of medication dispensed between the start and the end of the study period divided by the total number of days (365) in the study period.
cTime from the start of treatment to the discontinuation of treatment. Discontinuation was defined as a 60-day gap in once-daily teriparatide supply.